Orexigen Therapeutics to Present at Upcoming Investor Conferences

      Orexigen Therapeutics to Present at Upcoming Investor Conferences

PR Newswire

SAN DIEGO, Feb. 7, 2013

SAN DIEGO, Feb. 7, 2013 /PRNewswire/ --Orexigen® Therapeutics, Inc. (Nasdaq:
OREX) today announced that management will be presenting at two upcoming
investor conferences. The details are as follows:

The 15th Annual BIO CEO & Investor Conference
Date:         Tuesday, February 12, 2013
Time:         2:00 p.m. Eastern Time
Location:     The Waldorf Astoria, New York
2013 Leerink Swann Global Healthcare Conference
Date:         Wednesday, February 13, 2013
Time:         11:30 a.m. Eastern Time
Location:     The Waldorf Astoria, New York

The BIO CEO & Investor Conference presentation will be webcast live. To access
the webcast, please visit the Investor Relations section of the company's Web
site at www.orexigen.com. A replay will be available for 14 days after the
event.

About Orexigen® Therapeutics
Orexigen Therapeutics, Inc. is a biopharmaceutical company focused on the
treatment of obesity. The Company's lead product candidate is Contrave®, which
has completed Phase III clinical trials and for which a New Drug Application
has been submitted and reviewed by the FDA. The Company has also reached
agreement with the FDA on a Special Protocol Assessment for the Light Study,
the Contrave cardiovascular outcomes trial. The Company's other product
candidate, Empatic™, has completed Phase II clinical trials. Further
information about the Company can be found at www.orexigen.com.

Orexigen Contact:

McDavid Stilwell
VP, Corporate Communications and Business Development
(858) 875-8629

Media Contact:

Denise Powell
BrewLife
(510) 703-9491

SOURCE Orexigen Therapeutics, Inc.

Website: http://www.orexigen.com
 
Press spacebar to pause and continue. Press esc to stop.